D. E. Shaw & Co. Inc. Has $39.75 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

D. E. Shaw & Co. Inc. increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 171.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 831,414 shares of the biopharmaceutical company's stock after acquiring an additional 524,802 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.65% of Halozyme Therapeutics worth $39,750,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HALO. Norges Bank acquired a new stake in Halozyme Therapeutics during the fourth quarter worth $60,054,000. Capital World Investors acquired a new stake in Halozyme Therapeutics during the fourth quarter worth $35,773,000. Arrowstreet Capital Limited Partnership boosted its stake in Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after buying an additional 581,475 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Halozyme Therapeutics during the fourth quarter worth $21,838,000. Finally, Vanguard Group Inc. boosted its stake in Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after buying an additional 386,618 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HALO. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research note on Tuesday. HC Wainwright restated a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Finally, Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $62.10.

Halozyme Therapeutics Trading Down 24.6%

NASDAQ:HALO traded down $16.35 on Tuesday, hitting $50.23. 13,998,437 shares of the stock were exchanged, compared to its average volume of 1,556,329. The stock has a market capitalization of $6.19 billion, a price-to-earnings ratio of 14.64, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $70.51. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company's 50-day moving average price is $61.39 and its 200 day moving average price is $55.96.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company's quarterly revenue was up 35.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.79 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This represents a 0.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. The trade was a 12.95% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,697 shares of company stock worth $1,276,552. 2.40% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.